Scarica l'app Stockscreener
734.81
3.09%
-23.46
Dopo l'orario di chiusura:
736.80
1.99
+0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$758.27
Aprire:
$766.53
Volume 24 ore:
1.04M
Relative Volume:
1.41
Capitalizzazione di mercato:
$75.65B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
17.90
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
-7.69%
1M Prestazione:
-10.80%
6M Prestazione:
-5.46%
1 anno Prestazione:
+22.48%
Intervallo 1D:
$726.02
$777.43
Intervallo di 1 settimana:
$726.02
$803.87
Portata 52W:
$541.00
$859.34
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
734.81 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
506.74 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
188.94 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
936.00 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.89 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent - MedCity News
Baird reiterates Regeneron stock rating on Sanofi collaboration By Investing.com - Investing.com Canada
Sanofi To Pay Regeneron Up To $8B In Immunology Alliance - Law360
REGN Maintained by Jefferies -- Price Target Raised to $930 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00 - MarketBeat
Sanofi Commits Up to $8 Billion to Expand Regeneron Alliance on Next-Gen Antibodies - finance.biggo.com
Regeneron stock after-hours at EUR 660.45: minus 1.31 percent versus prior close - AD HOC NEWS
Jefferies raises Regeneron stock price target to $930 on partnership By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals (REGN) Reports Promising Ubamatamab Tr - GuruFocus
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion (NASDAQ:REGN) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Reports Promising Phase 1/2 Tri - GuruFocus
Why Regeneron (REGN) Stock Is Trading Lower Today - FinancialContent
Regeneron posts trial data for ovarian cancer therapy (REGN:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Unveils Positive Phase 2 COURAG - GuruFocus
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Sanofi and Regeneron expand global alliance - The Pharma Letter
Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients - TradingView
Sanofi to ‘ignite’ R&D in $8B deal with longstanding partner Regeneron - BioWorld News
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) - The Manila Times
Regeneron reports 73% response rate for ovarian cancer drug trial By Investing.com - Investing.com Canada
Sanofi, Regeneron broaden alliance to find their next Dupixent - Yahoo Finance
Patients in a small study had a median 11 months without ovarian cancer worsening on an experimental drug. - Stock Titan
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss - marketscreener.com
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal - WSJ
BMO reiterates Regeneron stock Outperform on Sanofi deal expansion By Investing.com - Investing.com Canada
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion - Benzinga
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion - MarketBeat
REGN: Expanded alliance targets next-gen type 2 medicines with equal cost/profit sharing and $8B in payments - TradingView
REGN Upgraded by Argus Research -- Price Target Announced at $85 - GuruFocus
Argus upgrades Regeneron stock to Buy with USD 850 target - AD HOC NEWS
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor - biospace.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus - MarketBeat
Upcoming Webinar Hosted by Xtalks: Inside Regeneron's Path to Scientific Intelligence and R&D Efficiency - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts - Yahoo Finance
Argus upgrades Regeneron stock rating to buy on Dupixent growth By Investing.com - Investing.com Canada
BreakingviewsCOMMENTARY: Sanofi’s Regeneron fix requires extra shot of M&A - reuters.com
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Finance
Sanofi and Regeneron expand immunology partnership to the tune of $8bn - Pharmaceutical Technology
Sanofi to invest up to $8bn to expand alliance with Regeneron - marketscreener.com
REGN Stock In Focus: Sanofi Expands Immunology Deal With $1B Upfront Payment And 4 New Antibodies - Stocktwits
Sanofi expands Regeneron partnership with up to $8 billion deal i - Global Banking & Finance Review
Sanofi Expands Collaboration with Regeneron in Immunology with $10 Billion Upfront Payment - GuruFocus
Regeneron, Sanofi expand alliance with $1 billion upfront deal By Investing.com - Investing.com Canada
Regeneron drug said to cut muscle loss when combined with Novo's semaglutide (REGN:NASDAQ) - Seeking Alpha
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion - Yahoo Finance
Sanofi and Regeneron Expand Antibody Collaboration - marketscreener.com
Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute - marketscreener.com
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies - The Manila Times
Regeneron and Sanofi Expand Long-Standing Collaboration to Add Next-Generation Long-Acting Immunology Antibodies in Deal Worth Up to $8 Billion - Quiver Quantitative
REGN: Expanded partnership targets next-gen immunology therapies, sharing costs, profits, and innovation - TradingView
Regeneron (REGN) Grants One-Time Performance Awards to CEO and CSO, Forms New Subsidiary - GuruFocus
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Sep 03 '26 |
Sale |
857.39 |
1,131 |
969,708 |
12,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Sale |
850.00 |
400 |
340,000 |
603 |
1.89%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):